RT Journal Article
SR Electronic
T1 BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.09.20245175
DO 10.1101/2020.12.09.20245175
A1 Ugur Sahin
A1 Alexander Muik
A1 Isabel Vogler
A1 Evelyna Derhovanessian
A1 Lena M. Kranz
A1 Mathias Vormehr
A1 Jasmin Quandt
A1 Nicole Bidmon
A1 Alexander Ulges
A1 Alina Baum
A1 Kristen Pascal
A1 Daniel Maurus
A1 Sebastian Brachtendorf
A1 Verena Lörks
A1 Julian Sikorski
A1 Peter Koch
A1 Rolf Hilker
A1 Dirk Becker
A1 Ann-Kathrin Eller
A1 Jan Grützner
A1 Manuel Tonigold
A1 Carsten Boesler
A1 Corinna Rosenbaum
A1 Ludwig Heesen
A1 Marie-Cristine Kühnle
A1 Asaf Poran
A1 Jesse Z. Dong
A1 Ulrich Luxemburger
A1 Alexandra Kemmer-Brück
A1 David Langer
A1 Martin Bexon
A1 Stefanie Bolte
A1 Tania Palanche
A1 Armin Schultz
A1 Sybille Baumann
A1 Azita J. Mahiny
A1 Gábor Boros
A1 Jonas Reinholz
A1 Gábor T. Szabó
A1 Katalin Karikó
A1 Pei-Yong Shi
A1 Camila Fontes-Garfias
A1 John L. Perez
A1 Mark Cutler
A1 David Cooper
A1 Christos A. Kyratsous
A1 Philip R. Dormitzer
A1 Kathrin U. Jansen
A1 Özlem Türeci
YR 2020
UL http://medrxiv.org/content/early/2020/12/11/2020.12.09.20245175.abstract
AB BNT162b2, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA (mRNA) encoding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S) stabilized in the prefusion conformation, has demonstrated 95% efficacy to prevent coronavirus disease 2019 (COVID-19). Recently, we reported preliminary BNT162b2 safety and antibody response data from an ongoing placebo-controlled, observer-blinded phase 1/2 vaccine trial1. We present here antibody and T cell responses from a second, non-randomized open-label phase 1/2 trial in healthy adults, 19-55 years of age, after BNT162b2 prime/boost vaccination at 1 to 30 µg dose levels. BNT162b2 elicited strong antibody responses, with S-binding IgG concentrations above those in a COVID-19 human convalescent sample (HCS) panel. Day 29 (7 days post-boost) SARS-CoV-2 serum 50% neutralising geometric mean titers were 0.3-fold (1 µg) to 3.3-fold (30 µg) those of the HCS panel. The BNT162b2-elicited sera neutralised pseudoviruses with diverse SARS-CoV-2 S variants. Concurrently, in most participants, S-specific CD8+ and T helper type 1 (TH1) CD4+ T cells had expanded, with a high fraction producing interferon-γ (IFNγ). Using peptide MHC multimers, the epitopes recognised by several BNT162b2-induced CD8+ T cells when presented on frequent MHC alleles were identified. CD8+ T cells were shown to be of the early-differentiated effector-memory phenotype, with single specificities reaching 0.01-3% of circulating CD8+ T cells. In summary, vaccination with BNT162b2 at well tolerated doses elicits a combined adaptive humoral and cellular immune response, which together may contribute to protection against COVID-19.Competing Interest StatementThe authors declare: U.S. and O.T. are management board members and employees at BioNTech SE (Mainz, Germany); A. K.-B., A.-K.E., A.U., C.R., D.B., P.K., D.L., D.M., E.D., J.G., J. S., M.-C.K., R.H., S. Bolte, S. Brachtendorf, T.P., U.L. and V.L. are employees at BioNTech SE; A.J.M., A.M., G.B., G.T.S., I.V., J.R., J.Q., K.K., L.M.K., N.B., and M.V. are employees at BioNTech RNA Pharmaceuticals GmbH; A.P. and J.Z.D are employees at BioNTech US; M.B. is an employee at Bexon Clinical Consulting LLC. A.B., C.A.K. and K.P. are employees of Regeneron Pharmaceuticals Inc; A.M., K.K., O.T. and U.S. are inventors on patents and patent applications related to RNA technology and COVID-19 vaccine; A.K.-B., J.Z.D., A.J.M., A.M., C.R., G.B., D.B., D.L., E.D., I.V., J.G., K.K., L.M.K., A.P., M.V., N.B., O.T., R.H., S. Bolte, U.L. and U.S. have securities from BioNTech SE; D.C., M.C., P.R.D., K.U.J. and J.L.P. are employees at Pfizer and may have securities from Pfizer; C.A.K. is an officer at Regeneron Pharmaceuticals, Inc; A.B., C.A.K. and K.P. have securities from Regeneron Pharmaceuticals, Inc; C.F.-G. and P.-Y.S. received compensation from Pfizer to perform the neutralisation assay; no other relationships or activities that could appear to have influenced the submitted work.Clinical TrialNCT04380701Funding StatementBioNTech is the Sponsor of the study and responsible for the design, data collection, data analysis, data interpretation, and writing of the report. Pfizer advised on the study and the manuscript, generated serological data, and contracted for the generation of serological data. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit the data for publication. All study data were available to all authors. This study was not supported by any external funding at the time of submission.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was carried out in Germany in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines and with approval by an independent ethics committee (Ethik-Kommission of the Landesaerztekammer Baden-Wuerttemberg, Stuttgart, Germany) and the competent regulatory authority (Paul-Ehrlich Institute, Langen, Germany).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request. Upon completion of this clinical trial, summary-level results will be made public and shared in line with data sharing guidelines.